Cell and gene therapies present an enormous opportunity for patients – the ability to insert or adapt genetic material is a true breakthrough for precision medicine and brings hope to those with previously incurable diseases. However, bringing these therapies to patients comes with enormous complexity – from research and approval through manufacturing and administration. In this episode, Jen and Mindy are joined by special guests Karen Baldry and Rebecca Sisselman to discuss the opportunities cell and gene therapies present, the challenges industry partners may be facing, and key considerations for navigating towards success.

For a recent example of Vynamic’s work in cell and gene therapy, check out our case study “Market Access Capability Analysis & Process Mapping for a Cell and Gene Therapy (CGT) Biotech”  

Podcast Tags: healthcare, life sciences, cell and gene therapy, gene therapy, rare disease, drug launch 

Source Links: 

• Eight imperatives for launching cell and gene therapies 
• Why Integrated Partners are Critical to Cell and Gene Therapy Success 
• Untangling the Complexities of Cell and Gene Therapy Clinical Trials: A Supply Chain Perspective 

Panel – Karen Baldry, Rebecca Sisselman, Mindy McGrath, Jen Burke 

Research & Production – Marc Young, Jen Burke 

Recording & Editing – Mike Liberto, Rachel Skonecki 

For additional discussion, please contact us at TrendingHealth.com or share a voicemail at 1-888-VYNAMIC.